

Name of Respondent		This Report Is: <input type="checkbox"/> (1) An Original <input type="checkbox"/> (2) A Resubmission	Date of Report (Mo, Da, Yr) / /	Year/Period of Report End of _____
<b>Annual Cost of Service Based Analysis Schedule</b>				
1.) Use footnotes when particulars are required or for any explanations. 2.) Enter on lines 1-9, columns (b) and (c), the value the respondent's Operating & Maintenance Expenses, Depreciation Expense, AFUDC Depreciation, Amortization of Deferred Earnings, Rate Base, Rate of Return, Return, Income Tax Allowance, and Total Cost of Service, respectively, for the end of the current and previous calendar years. The values shall be computed consistent with the Commission's Opinion No. 154-B et al. methodology. Any item(s) not applicable to the filing, the oil pipeline company shall report nothing in columns (b) and (c). 3.) Enter on line 10, columns (b) and (c), total interstate operating revenue, as reported on page 301, for the current and previous calendar years. 4.) Enter on line 11, columns b and c, the interstate throughput in barrels for the current and previous calendar years. 5.) Enter on line 12, columns b and c, the interstate throughput in barrel-miles for the current and previous calendar years. 6.) If the company makes major changes to its application of the Opinion No. 154-B et al. methodology, it must describe such changes in a footnote, and calculate the amounts in columns (b) and (c) of lines No. 1-12 using the changed application. 7.) A respondent may be requested by the Commission or its staff to provide its workpapers which support the data reported on page 700.				
Line No.	Item (a)	Current Year Amount (in dollars) (b)	Prior Year Amount (in dollars) (c)	
1	Operating and Maintenance Expenses	25,000,000	24,500,000	
2	Depreciation Expense	6,500,000	6,450,000	
3	AFUDC Depreciation	500,000	510,000	
4	Amortization of Deferred Earnings	800,000	840,000	
5	Rate Base			
5a	Rate Base – Original Cost	90,000,000	94,000,000	
5b	Rate Base – Unamortized Starting Rate Base Write-Up			
5c	Rate Base – Accumulated Net Deferred Earnings	20,000,000	21,000,000	
5d	Total Rate Base – Trended Original Cost – (line 5a + line 5b + line 5c)	110,000,000	115,000,000	
6	Rate of Return % (10.25% - 10.25)			
6a	Rate of Return – Adjusted Capital Structure Ratio for Long Term Debt	36.00	36.00	
6b	Rate of Return – Adjusted Capital Structure Ratio for Stockholders' Equity	64.00	64.00	
6c	Rate of Return – Cost of Long Term Debt Capital	8.00	8.00	
6d	Rate of Return – Real Cost of Stockholders' Equity	14.25	14.25	
6e	Rate of Return – Weighted Average Cost of Capital – (line 6a x line 6c + line 6b x line 6d)	12.00	12.00	
7	Return on Trended Original Cost Rate Base			
7a	Return on Rate Base – Debt Component – (line 5d x line 6a x line 6c)	3,168,000	3,312,000	
7b	Return on Rate Base – Equity Component – (line 5d x line 6b x line 6d)	10,032,000	10,488,000	
7c	Total Return on Rate Base – (line 7a + line 7b)	13,200,000	13,800,000	
8	Income Tax Allowance	9,000,000	9,400,000	
8a	Composite Tax Rate % (37.50% - 37.50)	37.50	37.50	
9	Total Cost of Service	55,000,000	55,500,000	
10	Total Interstate Operating Revenues	60,000,000	57,000,000	
11	Total Interstate Throughput in Barrels	80,000,000	79,000,000	
12	Total Interstate Throughput in Barrel-Miles	40,000,000,000	39,000,000,000	

[FR Doc. 2013-17729 Filed 7-23-13; 8:45 am]  
 BILLING CODE 6717-01-C

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

**21 CFR Parts 510, 522, and 524**

[Docket No. FDA-2013-N-0002]

**New Animal Drugs; Change of Sponsor; Fentanyl; Iron Injection**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Final rule.

**SUMMARY:** The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect a change of sponsor for two approved new animal drug applications (NADAs) from Alstoe, Ltd., Animal Health, to Sogeval S.A., and a change of sponsor for an NADA from Nexcyon Pharmaceuticals, Inc. to Elanco Animal Health, A Division of Eli Lilly & Co.

**DATES:** This rule is effective July 24, 2013.

**FOR FURTHER INFORMATION CONTACT:** Steven D. Vaughn, Center for Veterinary Medicine (HFV-100), Food and Drug Administration, 7520 Standish Pl., Rockville, MD 20855, 240-276-8300, email: [steven.vaughn@fda.hhs.gov](mailto:steven.vaughn@fda.hhs.gov).

**SUPPLEMENTARY INFORMATION:** Alstoe, Ltd., Animal Health, Pera Innovation Park, Nottingham Rd., Melton Mowbray, Leicestershire, England LE13 0PB has informed FDA that it has transferred ownership of, and all rights and interest in, NADA 099-667 for IMPOSIL (iron dextran complex) Injection and NADA 110-399 for GLEPTOSIL (gleptoferron) Injection to Sogeval S.A., 200 Avenue de Mayenne, 53000 Laval, France. Nexcyon Pharmaceuticals, Inc., 644 W. Washington Ave., Madison, WI 53703 has informed FDA that it has transferred ownership of, and all rights and interest in, NADA 141-337 for RECUVYRA (fentanyl) Transdermal Solution to Elanco Animal Health, A Division of Eli Lilly & Co., Lilly Corporate Center,

Indianapolis, IN 46285. Accordingly, the Agency is amending the regulations in 21 CFR parts 522 and 524 to reflect the transfers of ownership.

Following these changes of sponsorship, Alstoe, Ltd., Animal Health, and Nexcyon Pharmaceuticals, Inc., are no longer sponsors of approved NADAs. Accordingly, FDA is amending 21 CFR 510.600 to remove the entries for these firms.

In addition, Sogeval S.A. is now a sponsor of approved NADAs. Accordingly, FDA is amending 21 CFR 510.600 to add entries for this firm.

This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801–808.

**List of Subjects**

*21 CFR Part 510*

Administrative practice and procedure, Animal drugs, Labeling, Reporting and recordkeeping requirements.

*21 CFR Parts 522 and 524*

Animal drugs.

Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510, 522, and 524 are amended as follows:

**PART 510—NEW ANIMAL DRUGS**

■ 1. The authority citation for 21 CFR part 510 continues to read as follows:

**Authority:** 21 U.S.C. 321, 331, 351, 352, 353, 360b, 371, 379e.

■ 2. In the table in paragraph (c)(1) of § 510.600, remove the entries for “Alstoe, Ltd., Animal Health” and “Nexcyon Pharmaceuticals, Inc.”, and alphabetically add an entry for “Sogeval S.A.”; and in the table in paragraph (c)(2), remove the entries for “050929” and “062408”, and numerically add an entry for “059120” to read as follows:

**§ 510.600 Names, addresses, and drug labeler codes of sponsors of approved applications.**

*	*	*	*	*
(c)	*	*	*	*
(1)	*	*	*	*

Firm name and address	Drug labeler code
* * * *	*
Sogeval S.A., 200 Avenue de Mayenne, 53000 Laval, France .....	059120
* * * *	*

(2) \* \* \*

Drug labeler code	Firm name and address
*	*
059120 ....	Sogeval S.A., 200 Avenue de Mayenne, 53000 Laval, France.
*	*

**PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS**

■ 3. The authority citation for 21 CFR part 522 continues to read as follows:

**Authority:** 21 U.S.C. 360b.

**§ 522.1182 [Amended]**

■ 4. In § 522.1182, in paragraphs (b)(3) and (b)(8), remove “062408” and in its place add “059120”.

**PART 524—OPHTHALMIC AND TOPICAL DOSAGE FORM NEW ANIMAL DRUGS**

■ 5. The authority citation for 21 CFR part 524 continues to read as follows:

**Authority:** 21 U.S.C. 360b.

**§ 524.916 [Amended]**

■ 6. In paragraph (b) of § 524.916, remove “050929” and in its place add “000986”.

Dated: July 17, 2013.

**Bernadette Dunham,**  
*Director, Center for Veterinary Medicine.*  
 [FR Doc. 2013–17754 Filed 7–23–13; 8:45 am]

**BILLING CODE 4160–01–P**

**DEPARTMENT OF HOMELAND SECURITY**

**Coast Guard**

**33 CFR Part 165**

[Docket No. USCG–2013–0636]

RIN 1625–AA00

**Safety Zone; Metedeconk River; Brick Township, NJ**

**AGENCY:** Coast Guard, DHS.

**ACTION:** Temporary final rule.

**SUMMARY:** The Coast Guard is temporarily changing the enforcement date of a safety zone for one recurring fireworks display in the Fifth Coast Guard District. This regulation applies to only one recurring fireworks event held in the Metedeconk River in Brick Township, NJ. The fireworks display is normally held on the first Thursday in September, but this year it will be held on July 25th. The safety zone is necessary to provide for the safety of life on navigable waters during the event. This action is intended to restrict vessel traffic in a portion of Delaware River near Philadelphia, Pennsylvania, during the event.

**DATES:** This rule is effective from 6:30 p.m. on July 25, 2013 through September 5, 2013. Within the Coast Guard Sector Delaware Bay-COTP Zone portion of the table in 33 CFR 165.506, an entry 19 for the Metedeconk River, Brick Township, NJ Safety Zone will be added from 6:30 p.m. until 10 p.m. on July 25, 2013, and existing entry 9 will be suspended on September 5, 2013.

**ADDRESSES:** Documents mentioned in this preamble are part of docket [USCG–2013–0636]. To view documents mentioned in this preamble as being available in the docket, go to <http://www.regulations.gov>, type the docket number in the “SEARCH” box and click “SEARCH.” Click on Open Docket Folder on the line associated with this rulemaking. You may also visit the Docket Management Facility in Room W12–140 on the ground floor of the Department of Transportation West Building, 1200 New Jersey Avenue SE., Washington, DC 20590, between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays.

**FOR FURTHER INFORMATION CONTACT:** If you have questions on this rule, call or email Lieutenant Veronica Smith, U.S. Coast Guard Sector Delaware Bay, Chief of Waterways Management Division; telephone (215) 271–4851, email [veronica.l.smith@uscg.mil](mailto:veronica.l.smith@uscg.mil). If you have questions on viewing or submitting material to the docket, call Barbara